Top Research Papers from The Ottawa Hospital 2015-2017

June 7, 2018

Did you know that researchers at The Ottawa Hospital publish an average of four new scientific papers every single day? Our research is advancing science and improving health on a massive scale – both at home and around the world. The list below represents the “top research papers” from The Ottawa Hospital, as measured by Journal Impact Factor (for 2017) and citations (for 2015-2017), using several different categories. Read more about how the list was developed. Papers are referenced in the language in which they were written, however lay summaries are available in English and French. Researchers at The Ottawa Hospital are also affiliated with the University of Ottawa.

Top Papers of 2017 by Journal Impact Factor


  • Cardiotrophin 1 stimulates beneficial myogenic and vascular remodeling of the heart (Mohammad Abdul-Ghani, Colin Suen, Lynn Megeney, Duncan Stewart, Cell Research, JIF 15.6, paper, lay summary)
  • mTORC1 activates SREBP-2 by suppressing cholesterol trafficking to lysosomes in mammalian cells (Walaa Eid, Xiaohui Zha, PNAS, JIF 9.7, paper, lay summary)
  • Human Pluripotent Stem Cell-Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis (Lisa M. Julian, William Stanford, Cancer Research, JIF 9.3, paper, lay summary)
  • PCP and SAX-3/Robo Pathways Cooperate to Regulate Convergent Extension-Based Nerve Cord Assembly in C. elegans. (Pavak K. Shah, Mathew Tanner, Antonio Colavita, Developmental Cell, JIF 9.2, paper, lay summary)
  • NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine (Almohanad A. Alkayyal, Rebecca Auer, Cancer Immunology Research, JIF 8.3, paper, lay summary)

Clinical Research 

  • Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery (Dean Fergusson, New England Journal of Medicine, JIF 72.4, paperlay summary)
  • Reevaluation of Diagnosis in Adults With Physician-Diagnosed Asthma (Shawn Aaron, JAMA, JIF 44.4, paper, lay summary)
  • Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study (Marc Rodger, British Medical Journal, JIF 20.8, paper, lay summary)
  • Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial. (Lauralyn McIntyre, Dean Fergusson, American Journal of Respiratory and Critical Care Medicine, JIF 13.2, paper, lay summary)
  • Diagnostic Instability and Reversals of Chronic Obstructive Pulmonary Disease Diagnosis in Individuals with Mild to Moderate Airflow Obstruction (Shawn Aaron, American Journal of Respiratory and Critical Care Medicine JIF 13.2, paper)

Research Review, Methods and Policy Papers

  • Medical 3D printing and the physician-artist (Frank Rybicki, The Lancet, JIF 47.8, paper)
  • Patient Decision Aids to Engage Adults in Treatment or Screening Decisions (Dawn Stacey, JAMA, JIF 44.4, paper, lay summary)
  • Stop this waste of people, animals and money (David Moher, Nature, JIF 40.1, paper, lay summary)
  • Promote scientific integrity via journal peer review data (David Moher, Science, JIF 37.2, paper)
  • How to design efficient cluster randomised trials (Monica Taljaard, British Medical Journal, JIF 20.8, paper)
  • AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both (Beverley Shea, British Medical Journal, JIF 20.8, paper)
  • CONSORT-Equity 2017 extension and elaboration for better reporting of health equity in randomised trials (Peter Tugwell, Vivian Welch, British Medical Journal, JIF 20.8, paper)

Co-authored papers

  • Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism (Marc Carrier, New England Journal of Medicine, JIF 72.4, paper)
  • Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection (Curtis Cooper, New England Journal of Medicine, JIF 72.4, paper)
  • Angiotensin II for the Treatment of Vasodilatory Shock (Shane English, New England Journal of Medicine, 72.4, paper, lay summary)
  • Trial of Minocycline in a Clinically Isolated Syndrome of Multiple Sclerosis (Mark Freedman, New England Journal of Medicine, JIF 72.4, paper, lay summary)
  • Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism (Phil Wells, New England Journal of Medicine, JIF 72.4, paper, lay summary)

Top Papers of 2015-2017 by Citations


  • Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division (Nicolas A. Dumont, Michael Rudnicki, Nature Medicine, 2015, 64 citations, paper, lay summary)
  • Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity (Carolina Ilkow, John Bell, Nature Medicine, 2015, 38 citations, paper, lay summary)
  • Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension The PHACeT Trial (Duncan Stewart, Circulation Research 2015, 35 citations, paper, lay summary)
  • Human Endothelial Colony-Forming Cells Protect against Acute Kidney Injury (Dylan Burger, Kevin Burns, American Journal of Pathology, 2015, 34 citations, paper, lay summary)
  • Chronic Stress Induces Anxiety via an Amygdalar Intracellular Cascade that Impairs Endocannabinoid Signaling (Zhaohong Qin, Hsiao-Huei Chen, Neuron, 2015, 27 citations, paper, lay summary)
  • Striatal blood-brain barrier permeability in Parkinson's disease (John Woulfe; Journal of Cerebral Flow and Metabolism, 2015, 27 citations, paper)

Clinical Research 

  • Age of Transfused Blood in Critically Ill Adults (Dean Fergusson, Alan Tinmouth, New England Journal of Medicine, 2015, 216 citations, paper, lay summary)
  • Association Between Hospitalization for Pneumonia and Subsequent Risk of Cardiovascular Disease (Vicente Corrales-Medina, Journal of the American Medical Association, 2015, 85 citations, paper, lay summary)
  • Screening for Occult Cancer in Unprovoked Venous Thromboembolism (Marc Carrier, Marc Rodger, New England Journal of Medicine, 2015, 84 citations, paper, lay summary)
  • Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. (Glen Goss, Lancet Oncology 2016, 71 citations, paper, lay summary)
  • Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17 (Stephanie Brulé, Rachel Goodwin, European Journal of Cancer 2015, 66 citations, paper)

Research Review, Methods and Policy Papers 

  • Preferred reporting items for systematic review and meat-analysis protocols (PRISMA-P) 2015 statement (David Moher, Systematic Reviews, 1260 citations*, paper)
  • Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation (Larissa Shamseer, British Medical Journal, 641 citations, paper)
  • The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations (Brian Hutton, David Moher, Annals of Internal Medicine 2015, 310 citations, paper, lay summary)
  • A Systematic Review of Preclinical Studies on the Therapeutic Potential of Mesenchymal Stromal Cell-Derived Microvesicles (Celine Akyurekli, David Allan, Stem Cell Reviews and Reports, 2015, 75 citations, paper)
  • Intrinsic and extrinsic mechanisms regulating satellite cell function (Nicolas Dumont, Michael Rudnicki, Development 2015, 74 citations, paper)
  • Increasing value and reducing waste in biomedical research: who's listening? (David Moher, Lancet 2016, 56 citations, paper)
  • Part 3: Adult Basic Life Support and Automated External Defibrillation 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations (Christian Vaillancourt, Circulation 2015, 56 citations, paper)

Co-authored Papers 

  • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial (Christina Canil, The Lancet 2016, 614 citations, paper)
  • Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report (Phil Wells, Chest 2016, 612 citations, paper)
  • Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase III study (Joanne Meng, Lancet Oncology 2015, 404 citations, paper)
  • Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 (Lauralyn McIntyre, Intensive Care Medicine 2017, 233 citations, paper)
  • The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. (David Moher, PLOS Medicine 2015, 202 citations, paper)


The Ottawa Hospital: Inspired by research. Driven by compassion

The Ottawa Hospital is one of Canada’s largest learning and research hospitals with over 1,100 beds, approximately 12,000 staff and an annual budget of over $1.2 billion. Our focus on research and learning helps us develop new and innovative ways to treat patients and improve care. As a multi-campus hospital, affiliated with the University of Ottawa, we deliver specialized care to the Eastern Ontario region, but our techniques and research discoveries are adopted around the world. We engage the community at all levels to support our vision for better patient care. See for more information about research at The Ottawa Hospital.

University of Ottawa: —A crossroads of cultures and ideas

The University of Ottawa is home to over 50,000 students, faculty and staff, who live, work and study in both French and English. Our campus is a crossroads of cultures and ideas, where bold minds come together to inspire game-changing ideas. We are one of Canada’s top 10 research universities—our professors and researchers explore new approaches to today’s challenges. One of a handful of Canadian universities ranked among the top 200 in the world, we attract exceptional thinkers and welcome diverse perspectives from across the globe.

Media Contact

Jennifer Ganton Director, Communications and Public Relations Ottawa Hospital Research Institute Office: 613-798-5555 x 73325 Cell: 613-614-5253

*For this paper only, citations were obtained from Web of Science’s Medline database on date July 12, 2018. Citations for the other papers were obtained on April 12.